Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
A vast majority of drugs that are tested in animals fail to pass human clinical trials, resulting in delayed development and high costs. VeriSIM’s BIOiSIM platform, driven by artificial intelligence (AI) and machine learning (ML), de-risks R&D decisions by providing meaningful insights much earlier in the drug development process with unprecedented accuracy and scalability. This first-in-class solution significantly improves R&D productivity, one of the biggest pain points for pharmaceutical and biotech companies.
Ali Rajabi-Siahboomi, Vice President and Chief Innovation Officer at Colorcon, said, “VeriSIM aligns with Colorcon Ventures’ strategic focus on improving efficiencies in the drug development process. We believe VeriSIM can lower overall pharmaceutical development cost and accelerate time to market.”
Jo Varshney, VeriSIM’s Founder and CEO, said, “We are pleased to have Colorcon join us as a strategic investor. Access to Colorcon’s global R&D relationships and expertise should prove helpful as we scale VeriSIM in the years ahead.”
Colorcon Ventures joins a prominent list of investors who also participated in VeriSIM’s recently announced Series A, including Morpheus Ventures, Debiopharm Innovation Fund, OCA Ventures, Intel Capital, Serra Ventures and Susa Ventures.
by Colorcon, Press Release
Source: colorcon.com
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.
